Comparative Pharmacology
Head-to-head clinical analysis: MICAFUNGIN SODIUM versus REZZAYO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICAFUNGIN SODIUM versus REZZAYO.
MICAFUNGIN SODIUM vs REZZAYO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Micafungin inhibits 1,3-beta-D-glucan synthase, an enzyme required for synthesis of 1,3-beta-D-glucan, a key component of fungal cell walls.
Rezafungin is an echinocandin antifungal that inhibits the synthesis of 1,3-β-D-glucan, an essential component of the fungal cell wall, leading to osmotic instability and cell death.
100 mg intravenously once daily; for invasive candidiasis, a loading dose of 200 mg intravenously once on day 1 may be considered.
Intravenous: 2 mg/kg once daily, with a maximum of 200 mg per dose.
None Documented
None Documented
Terminal elimination half-life: 11–17 hours (mean ~14 hours) in healthy adults; prolonged in moderate-to-severe hepatic impairment (up to 20–30 hours).
Terminal elimination half-life approximately 13.3 hours in healthy subjects; at steady state, half-life ranges from 7.3 to 13.6 hours in patients with candidemia/invasive candidiasis.
Primarily hepatic metabolism; 71% recovered in feces (40% as parent drug, 31% as metabolite) and 11% in urine (1% as parent drug).
Elimination primarily via feces (approximately 60% of dose) and urine (approximately 20% of dose) as unchanged drug and metabolites.
Category C
Category C
Antifungal (Echinocandin)
Antifungal (Echinocandin)